Fuller's profit beat and buyout battle reshape its path
Strong Q2 earnings and raised guidance Fuller's second-quarter profit rose 19% to $1.41 per share, revenue grew 5.8%, and the company raised its full-year profit outlook. This shows the core business is performing well, which supports a higher stock price.
This is the main positive fundamental driver for FUL's price this period.
Acquisition of Advanced Medical Solutions Fuller agreed to buy Advanced Medical Solutions for £715 million, moving into higher-growth medical adhesives. The deal should boost long-term growth but will temporarily raise debt to about 4 times earnings, and an activist investor opposes it.
This is a major strategic move that affects FUL's growth and risk profile.
Ancora's buyout offer for building adhesives unit Ancora offered $1.1–1.2 billion for Fuller's Building Adhesives Solutions unit, but the board rejected it as too low. The offer highlights the unit's value and could pressure management to unlock it, potentially lifting the stock.
This event shows external interest in Fuller's assets and could lead to value creation.